HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Gudrun Simons
- Chirag Jhaveri (ORCID: https://orcid.org/0000-0002-4586-2590)
- Martin Gliem (ORCID: https://orcid.org/0000-0001-8215-6655)
- Yasir J. Sepah (ORCID: https://orcid.org/0000-0002-0104-6284)
- Sobha Sivaprasad (ORCID: https://orcid.org/0000-0001-8952-0659)
- Andrea Giani (ORCID: https://orcid.org/0000-0003-0682-1945)
- Quan Dong Nguyen (ORCID: https://orcid.org/0000-0002-6024-8441)
- Khaled Nassar (ORCID: https://orcid.org/0000-0003-4974-3828)
- Elizabeth Pearce (ORCID: https://orcid.org/0000-0002-8010-228X)
- Maged Habib (ORCID: https://orcid.org/0000-0003-0931-3786)
- Mohamed Ahmed
- Bartlomiej Krawczyk
Institutions
- Boehringer Ingelheim (Germany) (DE)
- NIHR Moorfields Biomedical Research Centre (GB)
- Retina Consultants of Texas (US)
- South Tyneside and Sunderland NHS Foundation Trust (GB)
- Photon Imaging (United States) (US)
- Moorfields Eye Hospital (GB)
- University College London (GB)
- Newcastle University (GB)
- The University of Texas at Austin (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.xops.2025.100781
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.12
Funders
- Roche
- Boehringer Ingelheim